ABRACL

Across TCGA pan-cancer cohorts, ABRACL mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ABRACL data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ABRACL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ABRACL expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

COAD, HNSC, and LSCC are the cancer types where ABRACL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	1.000	0.897	.044	12	view →
HNSC	DFS	Median	II,III,IV	0.883	0.682	.009	7	view →
LSCC	OS	Median	II,III,IV	1.000	0.884	.022	6	view →
PDAC	OS	Median	All	0.612	0.455	.024	5	view →
CCRCC	OS	Median	II,III,IV	0.970	0.722	.033	4	view →
GBM	OS	Median	All	0.451	0.598	.040	2	view →
LUAD	DFS	Tertile	All	0.529	0.918	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ABRACL–COAD (DFS)

Open the COAD breakdown →